Whalesbook
The National Company Law Tribunal (NCLT) has approved the proposed merger between Sequent Scientific and Viyash Life Sciences, a deal valued at approximately Rs 8,000 crore. This significant step, announced in September 2024, brings together Sequent's animal health business with Viyash's human pharmaceutical manufacturing capabilities, aiming to leverage back-end synergies. Carlyle Group, a major shareholder in both entities, is set to see its investment consolidated. The combined entity will be led by Viyash Life Sciences founder Hari Babu Bodepudi as CEO. This approval follows recent backing from Sequent Scientific's public shareholders.